Insulin detemir versus insulin glargine for type 2 diabetes mellitus
about
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic reviewConcepts and clinical use of ultra-long basal insulinCardiovascular effects of basal insulinsWeight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?rDNA insulin glargine U300 - a critical appraisalPrevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based StudiesTherapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice.Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.An assessment of randomized controlled trials (RCTs) for non-communicable diseases (NCDs): more and higher quality research is required in less developed countries.Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes.Insulin therapy and cancer in type 2 diabetes.Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trialsLong-acting basal insulin analogs: latest developments and clinical usefulness.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureasComparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabeteRates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT studyReal-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.Pharmacologic treatment of type 2 diabetes: injectable medications.The past, present, and future of basal insulins.Substitutes of Prescription Medicines - A Review of Concerns Relevant to Doctors and Patients.Therapeutic potency of saponin rich aqueous extract of Scoparia dulcis L. in alloxan induced diabetes in rats.Insulin detemir causes lesser weight gain in comparison to insulin glargine: role on hypothalamic NPY and galanin.Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol.Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus.COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.Comparative effectiveness and safety of different basal insulins in a real-world setting.Effectiveness and safety of insulin glargine detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis
P2860
Q24630395-FB4AF04E-EF3B-4519-8D49-F62992AFB40DQ26770354-33413CAC-4B47-4CB4-9B88-8149BAC07F48Q26800249-1FE15B27-C570-4CCB-BCD7-FA4B29844426Q27026774-1555D410-2636-4824-840E-81CC3772D954Q28077366-2E7F2A54-8AEC-41B6-9A1E-F92DFC4D34CBQ28084768-265BD1B2-0F8B-4EB1-A8CC-2758E71D9749Q30865883-BE010875-80EF-445C-B014-EB89E1237210Q33663452-E583CB10-1C70-4BD0-81C1-AAC9A883D27DQ33785179-99EE2729-EA8C-40B7-B841-06DE366EB15CQ35044151-91065492-00E6-49CA-8820-37E078B81BAFQ35134731-2BA4FAA3-BEE6-4F71-83EC-B6036CB1BFF3Q36273547-B8A7AAF6-693F-4897-A136-6207C7537169Q36328097-36410807-929E-4187-B5EF-4734E60B433FQ36417868-D62433CE-CCD1-4D87-84CC-F4DF9609DC53Q36426817-18A2B1BF-1955-476C-86AD-AE8C9481D818Q36515474-9EA8C98B-BAAC-4737-B139-29E64D3153F3Q36554243-569EF843-714B-4904-AF47-04A6B41D8D64Q36782811-DD6C70F5-F903-43A2-9C0E-3710425B8F4FQ36869489-A0919EEE-9C0B-4029-A787-39C25ECCDF53Q37272493-5FE4BFEE-E54E-4852-8243-4A0B7427D072Q37538487-D2A16926-CC8E-492B-A249-49AA94B75F01Q38176344-38C6AD22-2D50-42D5-8FED-76CF7BC8A54FQ38317168-CBFDA3E6-EB94-45C4-B14E-B21D6D5676C1Q38388602-16DF1925-3026-4C9A-BB9A-F652C7E0BEDEQ38618376-5C118773-E5DC-4AE4-9B13-FBD57908388EQ42029035-5EB67899-D466-4139-9878-5632A9EF82E3Q42046474-D5644679-FD23-4649-8B95-F285891502D4Q42062228-062D82DE-00CA-4762-84C1-CB148A7AE189Q42358420-7CAAE403-D4BB-44D5-9C1E-F26F73F6CDE6Q48089786-47DDB2B7-E2E6-4095-B253-073D39EA6DA0Q48623620-D32D509D-6D16-489C-891B-2F617CE41C6FQ52605864-DAD3A131-EE5A-4238-BB24-3039CC0AC768Q53484316-9CF28A46-B40C-414A-9554-ABFD7F9A8ABFQ58817760-A810B2F0-2911-4FBD-8745-262E17619C51
P2860
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@ast
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en-gb
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@nl
type
label
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@ast
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en-gb
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@nl
prefLabel
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@ast
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en-gb
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@nl
P2093
P2860
P3181
P1476
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
@en
P2093
Airin Cr Simon
Joost B Hoekstra
Sanne G Swinnen
P2860
P304
P3181
P356
10.1002/14651858.CD006383.PUB2
P577
2011-07-06T00:00:00Z